Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice

Ksiazek, 2003, A novel coronavirus associated with severe acute respiratory syndrome, N Engl J Med, 348, 1953, 10.1056/NEJMoa030781 Drosten, 2003, Identification of a novel coronavirus in patients with severe acute respiratory syndrome, N Engl J Med, 348, 1967, 10.1056/NEJMoa030747 Peiris, 2003, Coronavirus as a possible cause of severe acute respiratory syndrome, Lancet, 361, 1319, 10.1016/S0140-6736(03)13077-2 Rota, 2003, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, Science, 300, 1394, 10.1126/science.1085952 Marra, 2003, The genome sequence of the SARS-associated coronavirus, Science, 300, 1399, 10.1126/science.1085953 Zeng, 2003, The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39), Exp Biol Med (Maywood), 228, 866, 10.1177/15353702-0322807-13 Spruth, 2006, A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralizing and protective antibody responses, Vaccine, 24, 652, 10.1016/j.vaccine.2005.08.055 Qu, 2005, Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice, Vaccine, 23, 924, 10.1016/j.vaccine.2004.07.031 Jiang, 2005, SARS vaccine development, Emerg Infect Dis, 11, 1016, 10.3201/1107.050219 Zhou, 2006, A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice, Vaccine, 24, 3624, 10.1016/j.vaccine.2006.01.059 Woo, 2005, SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus, Vaccine, 23, 4959, 10.1016/j.vaccine.2005.05.023 Hamming, 2004, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J Pathol, 203, 631, 10.1002/path.1570 Lowell, 2004, Proteosome™ technology for vaccines and adjuvants, 271 Jones, 2006, Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection, Vaccine, 24, 1625, 10.1016/j.vaccine.2005.09.052 Jones, 2004, Protollin: a novel adjuvant for intranasal vaccines, Vaccine, 22, 3691, 10.1016/j.vaccine.2004.03.035 Mallett, 1995, Intranasal or intragastric immunization with proteosome–Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection, Infect Immun, 63, 2382, 10.1128/IAI.63.6.2382-2386.1995 Fries, 2001, Safety and immunogenicity of a proteosome–Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults, Infect Immun, 69, 4545, 10.1128/IAI.69.7.4545-4553.2001 Plante, 2001, Nasal immunization with subunit proteosome influenza vaccines induce serum HAI, mucosal IgA and protection against Influenza challenge, Vaccine, 20, 218, 10.1016/S0264-410X(01)00268-7 Roberts, 2005, Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans, J Virol, 79, 5833, 10.1128/JVI.79.9.5833-5838.2005 Zakhartchouk, 2005, Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines, Vaccine, 23, 4385, 10.1016/j.vaccine.2005.04.011 Reed, 1938, A simple method of estimating fifty per cent endpoints, Am J Hygiene, 27, 493 Frasca, 2005, Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans, Semin Immunol, 17, 378, 10.1016/j.smim.2005.05.005